Table 4.
COVID-19 patients developing AKI or not: univariate analysis (admission and in-hospital stay).
| Patients, n | AKI (n = 119) |
No AKI (n = 268) |
p |
|---|---|---|---|
| Medical therapy during hospital stay: | |||
| Antibiotics, n | 108 (91.5%) | 211 (78.7%) | 0.001 |
| Antivirals, n | 42 (35.3%) | 105 (39.3%) | NS |
| Diuretics, n | 49 (41.5%) | 84 (31.3%) | 0.035 |
| FANS, n | 28 (23.5%) | 59 (22%) | NS |
| Glucocorticoids, n | 59 (50%) | 100 (37.4%) | 0.01 |
| Heparin, n | 101 (85.5%) | 225 (83.9%) | NS |
| Hydroxychloroquine, n | 103 (87.3%) | 239 (89.5%) | NS |
| ACEIs/ARBs, n | 48 (40.3%) | 92 (34.3%) | NS |
| Clinical parameters during in-hospital stay: | |||
| Multi Organ Failure (MOF), n | 7 (5.9%) | 3 (1.1%) | 0.01 |
| Haemodialysis (HD), n | 6 (5%) | 0 | 0.001 |
| Severe COVID-19, n | 86 (94.5%) | 149 (86.1%) | 0.02 |
| COVID-19 related pneumonia, n | 117 (98%) | 255 (95.1%) | NS |
| Sepsis, n | 31 (26%) | 36 (13.4%) | 0.002 |
| Biochemistries at admission: | |||
| IL-6, pg/mL | 159.6 ± 195 | 65.3 ± 74 | 0.0001 |
| LDH, IU/L | 399.8 ± 197.8 | 316.78 ± 161.4 | 0.001 |
| PCR, mg/dL | 12.2 ± 10 | 11.6 ± 25.5 | NS |
| D-dimer, mcg/mL | 5663.64 ± 26791.1 | 3873.6 ± 20173.3 | NS |
| Ferritin, ng/mL | 2264.3 ± 3518,4 | 1103.1 ± 1145.7 | 0.001 |
| ALT, IU/L | 99.3 ± 375.5 | 53.1 ± 78.9 | NS |